Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Making Ocular Nanoparticle Uptake Causal
2026-09-29
Cytochalasin D transforms corneal nanoparticle uptake from a descriptive endpoint into a mechanistic experiment. This thought-leadership guide connects actin remodeling, epithelial barriers, assay controls, and translational decision-making for ocular nanomedicine researchers.
-
Biodentine Rejuvenates Aging Dental Pulp Stem Cells
2026-09-28
The reference study shows that Biodentine promotes proliferation and reduces senescence-associated features in human dental pulp stem cells, particularly through Wnt/β-catenin signaling. Its age-stratified design links a clinically relevant pulp-capping material with a cellular anti-aging mechanism while also defining important boundaries for translating the findings into culture workflows.
-
EAGLE-2 and EAGLE-3: Gepotidacin uUTI Trial Design
2026-09-28
The reference paper describes the rationale and design of two large, near-identical Phase III trials comparing oral Gepotidacin with nitrofurantoin for uncomplicated urinary tract infection in female participants. Its central contribution is a guidance-aligned, double-blind noninferiority framework with a combined clinical and microbiological endpoint—not clinical efficacy results.
-
Cimetidine in BBB and H2 Research Workflows
2026-09-27
Use Cimetidine to connect H2-receptor experiments with carefully controlled permeability studies—without treating an exploratory BBB result as established pharmacology. This workflow pairs practical formulation guidance with a high-throughput barrier-model framework and clear troubleshooting checkpoints.
-
Zosuquidar (LY335979): A P-gp Workflow Guide
2026-09-26
Use Zosuquidar to test whether P-glycoprotein efflux is limiting chemotherapy response, then pair functional drug-accumulation measurements with viability and transporter-expression readouts. This practical guide covers an in-vitro sensitization workflow, context-aware pharmacokinetic questions, and troubleshooting for multidrug-resistance studies.
-
ARCA EGFP mRNA for Transfection Assays
2026-09-25
Use ARCA EGFP mRNA to measure functional mRNA delivery and protein expression with a direct fluorescence readout, then apply the same assay logic to compare delivery conditions. A practical workflow pairs dose and time-course pilots with careful controls—especially when extending from easy-to-transfect cells to macrophage-focused lipid nanoparticle research.
-
Iron-Dependent KDM4D Sets MSC Quiescence–Activity Balance
2026-09-25
The study links iron deficiency to reduced KDM4D demethylase activity, increased H3K9me3 near the PIK3R3 promoter, and impaired activation of mesenchymal stem cells through the PI3K–Akt–Foxo1 pathway. Its findings connect an iron-sensitive epigenetic mechanism with bone-mass loss in mice and identify pathway modulation as a potential experimental means of testing this relationship.
-
HA Tag Peptide for Mechanistic Protein Studies
2026-09-24
The Influenza Hemagglutinin (HA) Peptide is more than an elution reagent: it can help researchers design cleaner tests of protein abundance, interaction, and modification. This article connects HA-tag workflows to the NEDD4L–PRMT5 colorectal cancer metastasis findings while clarifying what those assays can—and cannot—prove.
-
NEDD4L Limits Colorectal Cancer Liver Metastasis
2026-09-24
An in vivo loss-of-function screen identified NEDD4L as a suppressor of colorectal cancer liver metastasis. The study links NEDD4L-mediated PRMT5 degradation to reduced AKT1 arginine methylation and inhibition of AKT/mTOR signaling, offering a mechanistic framework for further metastasis research.
-
Tomentodione M Reverses P-gp–Linked Drug Resistance
2026-09-23
Zhou and colleagues found that tomentodione M sensitized multidrug-resistant MCF-7/MDR and K562/MDR cells to docetaxel and doxorubicin while reducing P-glycoprotein expression. Their experiments link this effect to inhibition of p38 MAPK signaling, offering a mechanistic basis for further studies of drug-efflux-associated resistance—not evidence of clinical efficacy.
-
Copper Single-Atom MOF for Ultrasound-Enhanced Therapy
2026-09-23
Wang and colleagues developed FNUC, a folic-acid-modified NH2-UiO-66 framework containing isolated copper sites for glutathione depletion and ultrasound-enhanced chemodynamic therapy. The study links single-atom catalysis with NIR-II fluorescence imaging using IR-1061, providing a combined strategy for tumor localization and reactive oxygen species generation.
-
Iptacopan Monotherapy in Paroxysmal Hemoglobinuria
2026-09-22
This phase 2 proof-of-concept study found that oral Iptacopan (LNP023) monotherapy rapidly reduced hemolysis and improved hemoglobin and transfusion outcomes in treatment-naive patients with active paroxysmal nocturnal hemoglobinuria. Its two-cohort design provides early clinical evidence that proximal alternative-pathway inhibition can address hemolysis beyond terminal C5 blockade, while the small, open-label interim dataset limits broader conclusions.
-
Selonsertib (GS-4997): Assay Reliability Guide
2026-09-22
A scenario-driven guide to using Selonsertib (GS-4997), SKU B7812, in viability, proliferation, oxidative-stress, inflammation, and fibrosis experiments. It links assay design, solvent control, pathway-specific interpretation, and practical product-selection criteria for more reproducible research workflows.
-
Cimetidine: From H2 Biology to Barrier Strategy
2026-09-21
A mechanism-first guide to using Cimetidine in gastrointestinal cancer research, H2 receptor pathway studies, and carefully designed blood-brain barrier workflows.
-
ARCA EGFP mRNA as a Quantitative Delivery Control
2026-09-21
ARCA EGFP mRNA is more than a fluorescent transfection marker: it can help separate delivery, cytosolic access, translation, and cell-state effects in mammalian assays. This article develops an evidence-grounded framework that combines reporter fluorescence with impedance-based monitoring for more interpretable delivery studies.